Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,038,600 shares, an increase of 33.0% from the September 30th total of 780,900 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is presently 10,386.0 days.

Swedish Orphan Biovitrum AB (publ) Price Performance

Shares of OTCMKTS BIOVF opened at $32.01 on Friday. Swedish Orphan Biovitrum AB has a 1 year low of $19.55 and a 1 year high of $32.25. The stock has a market capitalization of $9.45 billion, a P/E ratio of 53.35 and a beta of 0.56. The company’s 50-day moving average is $29.49 and its 200 day moving average is $26.90. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.